Diabeloop
Medtech company developing therapeutic artificial-intelligence systems to automate and personalize insulin therapy. The company develops self‑learning control algorithms that integrate continuous glucose monitoring and insulin delivery devices to provide hybrid closed‑loop automated insulin delivery. Activities include clinical validation, regulatory submissions and approvals in Europe and the United States, commercialization across multiple European countries, operation of clinician-facing data analysis and telemonitoring platforms, and partnerships for device integration and distribution. Recent regulatory milestones include CE marking in Europe and a US regulatory clearance for a smartphone-hosted automated insulin delivery algorithm.
Industries
Nr. of Employees
medium (51-250)
Diabeloop
Patents
Computerized system and method for the determination of a drug dosage, and computer program
US-12592307-B2
View DetailsMethod for determining an uncertainty level of deep reinforcement learning network and device implementing such method
US-12036391-B2
View Details
Computerized system and method for the determination of a drug dosage, and computer program
US-12592307-B2
View DetailsMethod for determining an uncertainty level of deep reinforcement learning network and device implementing such method
US-12036391-B2
View DetailsProducts
Automated insulin delivery system (hybrid closed-loop, smartphone-hosted option)
Hybrid closed-loop therapy combining a self-learning insulin dosing algorithm hosted on a user smartphone or dedicated terminal, continuous glucose monitoring, and an insulin delivery device to automate insulin dosing decisions.
Clinical data management and analysis platform
A clinician-facing platform for consultation, visualization and analysis of patient glycemic events to support therapy adjustment and remote monitoring workflows.
Mobile applications for connected insulin pens and smartphone-based closed-loop access
Smartphone applications to support users with connected insulin pens and to deliver closed-loop functionality via mobile devices.
DBLG1
A self-learning algorithm that automates and personalizes the treatment of Type 1 diabetes, acting as a hybrid closed-loop system.
DBL-hu
An automated solution for the management of highly unstable Type 1 diabetes.
Yourloops
A data management platform for remote diabetes data monitoring and therapy management.
Automated insulin delivery system (hybrid closed-loop, smartphone-hosted option)
Hybrid closed-loop therapy combining a self-learning insulin dosing algorithm hosted on a user smartphone or dedicated terminal, continuous glucose monitoring, and an insulin delivery device to automate insulin dosing decisions.
Clinical data management and analysis platform
A clinician-facing platform for consultation, visualization and analysis of patient glycemic events to support therapy adjustment and remote monitoring workflows.
Mobile applications for connected insulin pens and smartphone-based closed-loop access
Smartphone applications to support users with connected insulin pens and to deliver closed-loop functionality via mobile devices.
DBLG1
A self-learning algorithm that automates and personalizes the treatment of Type 1 diabetes, acting as a hybrid closed-loop system.
DBL-hu
An automated solution for the management of highly unstable Type 1 diabetes.
Yourloops
A data management platform for remote diabetes data monitoring and therapy management.
Services
Collaborative development agreements and technical integration services to connect insulin delivery algorithms with partner devices and sensors.
Integration of device data streams with telemonitoring platforms and clinician analytics to support remote follow-up and therapy adjustments.
Market launch support and distribution of medical device systems across European markets including coordination with local distributors and payers.
Collaborative development agreements and technical integration services to connect insulin delivery algorithms with partner devices and sensors.
Integration of device data streams with telemonitoring platforms and clinician analytics to support remote follow-up and therapy adjustments.
Market launch support and distribution of medical device systems across European markets including coordination with local distributors and payers.
Expertise Areas
- Automated insulin delivery systems
- Therapeutic artificial intelligence for diabetes
- Clinical trial management and multicenter studies
- Medical device regulatory compliance (CE marking, EU MDR, FDA 510(k))
Key Technologies
- Self-learning closed-loop control algorithms
- Smartphone-hosted therapeutic mobile applications
- Continuous glucose monitoring (CGM) integration
- Wireless device communication (Bluetooth Low Energy)
News & Updates
Announcement of CE marking and phased European commercial launch of a smartphone-hosted automated insulin delivery system integrated with third-party continuous glucose monitors and patch pumps.
Announcement of regulatory clearance from US authorities for a smartphone-hosted automated insulin delivery algorithm.
Scientific team presentations and posters on algorithmic evolution, one-year real-world system use, gender analysis of physical activity management, and long-term safety and effectiveness of the system.
Announcement of data synchronization between the insulin delivery system and a telemonitoring platform to enable remote clinical follow-up in France; integration complements the company's clinician analysis platform.
Public communication on cooperation to evolve the distribution model for a patch pump in France and the manufacturer establishing a local commercial entity.
Overview of company formation, clinical trials, CE marking, fundraising rounds, international expansion and commercial launch across Europe.
Announcement of CE marking and phased European commercial launch of a smartphone-hosted automated insulin delivery system integrated with third-party continuous glucose monitors and patch pumps.
Announcement of regulatory clearance from US authorities for a smartphone-hosted automated insulin delivery algorithm.
Scientific team presentations and posters on algorithmic evolution, one-year real-world system use, gender analysis of physical activity management, and long-term safety and effectiveness of the system.
Announcement of data synchronization between the insulin delivery system and a telemonitoring platform to enable remote clinical follow-up in France; integration complements the company's clinician analysis platform.
Public communication on cooperation to evolve the distribution model for a patch pump in France and the manufacturer establishing a local commercial entity.
Overview of company formation, clinical trials, CE marking, fundraising rounds, international expansion and commercial launch across Europe.